Belviq (lorcaserin) side effects: Seasonal allergy in 3.1% of patients vs 0.8% with placebo

Posted by .(JavaScript must be enabled to view this email address)
Saturday, June 22, 2013 1:28 pm Email this article

Seasonal allergy was reported in 3.1% of patients given the weight loss drug, Belviq (lorcaserin), versus 0.8% of patients given a placebo according to studies performed leading up to the FDA approval of the drug.

Reference

Belviq (lorcaserin hydrochloride) Prescribing Information. Revision 08/2012.
http://www.belviq.com/pdf/Belviq_Prescribing_information.pdf

 

Articles on the same subject can be found here:

• Belviq (lorcaserin hydrochloride)